Last reviewed · How we verify

Pregistry — Portfolio Competitive Intelligence Brief

Pregistry pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Antiviral Agents Antiviral Agents phase 3 Antiviral agent Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Hadassah Medical Organization · 1 shared drug class
  2. Institut de Recherche pour le Developpement · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Pregistry:

Cite this brief

Drug Landscape (2026). Pregistry — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pregistry. Accessed 2026-05-15.

Related